Literature summary for 1.1.99.1 extracted from

Konstantinova, S.V.; Tell, G.S.; Vollset, S.E.; Nygard, O.; Bleie, O.; Ueland, P.M.
Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women (2008), J. Nutr., 138, 914-920.

Search for more literature for 1.1.99.1

Application

Application	Comment	Organism
medicine	population-based study, relation of plasma choline and betaine to smoking, physical activity, BMI, percent body fat, waist circumference, blood pressure, serum lipids and glucose	Homo sapiens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
mitochondrion	-	Homo sapiens	5739	-

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
choline + acceptor	Homo sapiens	-	betaine aldehyde + reduced acceptor	-	?

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q8NE62	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
blood plasma	choline and betaine levels	Homo sapiens	-

Specific Activity [micromol/min/mg]

Specific Activity Minimum [µmol/min/mg]	Specific Activity Maximum [µmol/min/mg]	Comment	Organism
additional information	-	population-based study, unfavorable cardiovascular risk factor profile associated with high choline and low betaine concentrations, choline and betaine associated in opposite directions with key components of metabolic syndrome, disruption of mitochondrial choline dehydrogenase pathway	Homo sapiens

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
choline + acceptor	-	Homo sapiens	betaine aldehyde + reduced acceptor	-	?
choline + acceptor	relation of plasma choline and betaine to cardiovascular risk factors, mitochondrial choline dehydrogenase pathway	Homo sapiens	betaine aldehyde + reduced acceptor	-	?

Synonyms

Synonyms	Comment	Organism
ChoDH	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)